T. Rowe Price CEO: $20B in client outflows ‘clearly the missing ingredient’

T. Rowe's CEO Rob Sharps, in discussing the firm's second quarter results, said outflows should get better in 2024 and that the company is poised to return to organic growth in 2025.

Roseville-based Helios Quantitative Research adds custom tools for financial advisers

Truist Financial top analysts’ expectations on Q4 earnings, revenue as CEO touts ‘post-integration momentum’

What 30 years of experience has taught this Philadelphia VP and portfolio manager about investing

5 Minutes With… connectRN chief executive Ted Jeanloz

Viewpoint: City’s efforts can help housing, but we have to get it right

Funeral home in Denver’s Berkeley neighborhood could be demolished to make way for 58 townhomes

Clutch Brewing at Keg & Case food hall will close

Kentwood new office dazzles

T. Rowe Price CEO: $20B in client outflows ‘clearly the missing ingredient’

Previous Federated Hermes CEO talks strength in numbers, both Q2 results and family dynamics

Next Biogen to buy DFW rare disease firm for $7.2B

firststargroup

Kotek touts $500M Oregon housing plan at Leadership Summit

Retirement plans see boost as states mandate IRAs and tax credits lower costs

Norton Healthcare data breach affected more than 2 million people

Houston-based cell therapy company FibroBiologics files to go public

Suggested Posts

The Langer family and OnPoint Community Credit Union⁠: When commercial success builds community

Golden Valley Country Club raising initiation fee by $8K following course renovation

MIDAS Healthcare gets $2 million investment for 2024 product launch

Redstone acquires another warehouse property in the Albany region

Bog & Barley gets opening date for its elevated Irish fare in East Memphis

Samsung needs 170 construction workers ASAP for Central Texas factory

MENU

FirstStar Group

More Stories

CFO of the Year honoree: Anker Christensen, River City Bank

Previous Federated Hermes CEO talks strength in numbers, both Q2 results and family dynamics

Next Biogen to buy DFW rare disease firm for $7.2B

firststargroup

Related Posts

Suggested Posts

MENU

FirstStar Group

More Stories